CD47 and neoplasm: In addition, increased receptors on the RR GBM cells may efficiently consume anti-CD47 antibodies before it reaches the threshold concentration sufficient for tumor cell elimination, especially in the case of GBM with the challenge of antibody crossing the blood–brain barrier (BBB) or blood–tumor barrier (BTB).